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Dynamics of IL-4 and IL-13 expression in the
airways of sheep following allergen challenge
Bahar Liravi1, David Piedrafita2, Gary Nguyen1 and Robert J. Bischof1,3*
Abstract
Background: IL-4 and IL-13 play a critical yet poorly understood role in orchestrating the recruitment and
activation of effector cells of the asthmatic response and driving the pathophysiology of allergic asthma. The house
dust mite (HDM) sheep asthma model displays many features of the human condition and is an ideal model to
further elucidate the involvement of these critical Th2 cytokines. We hypothesized that airway exposure to HDM
allergen would induce or elevate the expression profile of IL-4 and IL-13 during the allergic airway response in this
large animal model of asthma.
Methods: Bronchoalveolar lavage (BAL) samples were collected from saline- and house dust mite (HDM)-
challenged lung lobes of sensitized sheep from 0 to 48 h post-challenge. BAL cytokines (IL-4, IL-13, IL-6, IL-10, TNF-
α) were each measured by ELISA. IL-4 and IL-13 expression was assessed in BAL leukocytes by flow cytometry and
in airway tissue sections by immunohistology.
Results: IL-4 and IL-13 were increased in BAL samples following airway allergen challenge. HDM challenge resulted
in a significant increase in BAL IL-4 levels at 4 h compared to saline-challenged airways, while BAL IL-13 levels were
elevated at all time-points after allergen challenge. IL-6 levels were maintained following HDM challenge but
declined after saline challenge, while HDM administration resulted in an acute elevation in IL-10 at 4 h but no
change in TNF-α levels over time. Lymphocytes were the main early source of IL-4, with IL-4 release by alveolar
macrophages (AMs) prominent from 24 h post-allergen challenge. IL-13 producing AMs were increased at 4 and
24 h following HDM compared to saline challenge, and tissue staining provided evidence of IL-13 expression in
airway epithelium as well as immune cells in airway tissue.
Conclusion: In a sheep model of allergic asthma, airway inflammation is accompanied by the temporal release of
key cytokines following allergen exposure that primarily reflects the Th2-driven nature of the immune response in
asthma. The present study demonstrates for the first time the involvement of IL-4 and IL-13 in a relevant large
animal model of allergic airways disease.
Background
Asthma is a chronic inflammatory disease of the lungs
characterized by inflammation, airway hyperresponsiveness
(AHR) and airway wall remodelling. Atopic asthmatics
display high levels of allergen-specific immunoglobulin E
(IgE) antibodies, and this is associated with the develop-
ment of a type 2 immune response with evidence of
elevated expression levels of T-helper type 2 (Th2) cyto-
kines [1].
The Th2 cytokines, including interleukin (IL)-4, IL-5, IL-
9, IL-13 and IL-25, together promote key pathophysio-
logical features of asthma including allergen-specific IgE,
airway inflammation (characterized by activated lympho-
cytes, eosinophils, mast cells and macrophages), damage
to the airway epithelium, mucus gland hyperplasia and
structural remodelling of the airway wall [2–4]. Other
cytokines have been implicated in the pathogenesis of
asthma. For example, IL-6 is a marker of inflammation
and serves as an important regulator of effector CD4+ T
cell fate by promoting IL-4 production during Th2 differ-
entiation while inhibiting Th1 differentiation [5]. An
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immunoregulatory role for IL-6 in asthma and other
pulmonary diseases where the lung epithelium is damaged
has been highlighted [6].
There is strong evidence that IL-4 and IL-13 play a cru-
cial role in orchestrating the recruitment and activation of
the effector cells of the asthmatic response. IL-4 is an
essential trigger for Th2 lymphocyte differentiation, and
both IL-4 and IL-13 can induce IgE class switching in B
lymphocytes. Additionally, IL-4 and IL-13 act on bron-
chial epithelial, endothelial and airway smooth muscle
cells, collectively leading to many of the pathophysio-
logical features of asthma [3, 7].
Clinical observations of IL-4 in allergic asthma include
increased IL-4 in the serum and bronchoalveolar lavage
(BAL) of allergic individuals [8, 9], while nebulized IL-4
given to patients with mild asthma results in a significant
increase in AHR associated with the elevation of sputum
eosinophil numbers [10]. Studies using IL-4 deficient mice
indicate that the main role of IL-4 in allergic airway
inflammation is during the initial priming of Th2 effector
cells [3, 11].
In murine and human studies, IL-13 has been shown to
be directly responsible for eosinophil survival and prolifer-
ation within lung tissue, the release of mediators respon-
sible for bronchoconstriction and the induction of mucus
hypersecretion (reviewed in [12]). IL-13 mRNA expression
has been reported in bronchial biopsies from both allergic
and non-allergic asthmatic subjects [13], and IL-13 in
BAL following allergen provocation of asthmatic subjects
is strongly correlated with an increase in eosinophil num-
bers [14, 15]. In mice, human IL-13 promotes many of the
inflammatory changes associated with asthma, such as
inflammatory cell infiltration in the lungs and AHR and
goblet cell metaplasia [16, 17]; treatment with an anti- IL-
13 monoclonal antibody (mAb) has been shown to be
effective in mice [18], although poorer outcomes have
been realised to date in human clinical trials [19, 20].
A sheep model of asthma based on the relevant aller-
gen house dust mite (HDM) displays many key features
of the human asthmatic condition [21, 22]. Sheep sensi-
tized to HDM develop allergen-specific IgE responses,
inflammation of the airways following airway allergen
challenge that includes profound eosinophilia, airway
epithelial mucus hypersecretion, airway wall remodelling
and early and late-phase asthmatic responses and AHR
following airway allergen challenge [22–24]. Unfortu-
nately, our current understanding of the role of Th2-
cytokines in larger animal models of asthma, where
experimental therapeutic and in real-time manipulation
is viable, is limited to a description or phenotypic ana-
lysis of inflammatory cells involved in the allergic re-
sponse (reviewed in [25, 26]), and a single study in non-
human primates reporting elevated mRNA expression of
IL-4 and IL-13 in HDM-challenged airways [27].
The current study aimed to investigate the expression
of IL-4 and IL-13, as well as IL-6, IL-10 and TNF-α, in
the sheep model of asthma following allergen challenge
of the airways. We hypothesized that airway allergen
challenge would induce an elevated expression profile of
two critical Th2 cytokines, IL-4 and IL-13, in the HDM
sheep model of allergic asthma.
Methods
Animals and HDM sensitization and challenge protocols
Merino-cross ewes (8–12 months old), treated orally with
anthelminthic to eliminate any worm parasites prior to
the experiment, were housed in indoor pens and fed ad
libitum. All experimental work was approved by the
Monash University Animal Ethics Committee.
Sheep were sensitized by subcutaneous immunizations
with a solubilized preparation of house dust mite extract
(HDM; CSL Ltd, Parkville, Australia) as detailed else-
where [23, 28]. Sensitized animals (HDM-specific IgE re-
sponders) were rested for 3 weeks, then given segmental
airway challenges with HDM (500 μg in 5 ml) at weekly
intervals over 3 weeks (ie. three challenges over 3 weeks)
using a flexible fibre-optic endoscope (Model FG-16×,
Pentax, NJ, USA). The airway challenges for each animal
involved a segmental bolus infusion of 5 ml HDM solution
into each of 3 discrete lung lobes (HDM administered
only to the left caudal, right caudal and right middle lobes;
see Fig. 1 and [22]) and a 5 ml infusion of sterile saline
into each of three control lung lobes (saline administered
Saline
HDM
Fig. 1 Ovine lung diagram indicating the location of lung segments
used for the bronchoscopic delivery of HDM (solid line) and saline
control (broken line) treatments within the same sheep
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only to the left cranial, right cranial and accessory lobes;
Fig. 1 and [22]). Thus, over the entire period of airway
challenges, each separate lung lobe was exposed to only
saline or HDM; further, in each animal and on each chal-
lenge occasion, HDM and saline segmental challenges
were given at the same time-point. At the time of the third
and final airway challenge with saline/HDM, BAL collec-
tions were performed on individual lobes for subsequent
cellular and cytokine analyses (as detailed below).
Bronchoalveolar lavage (BAL) sampling
On the occasion of the final (3rd) airway challenge, BAL
collections with sterile saline were performed on separate
lung lobes at 0, 4, 24 and 48 h following airway saline/
HDM challenge using a fibre-optic endoscope [23, 28]
and samples placed on ice before being centrifuged at 400
g to separate BAL cells from BAL fluid. BAL fluid samples
were concentrated by centrifugation filtration using 3 kDa
nominal molecular weight limit devices (Amicon Ultra-15,
Millipore, Bedford, MA, USA) following the manufacturer
instructions and stored at −80 °C prior to cytokine
quantitation (see below). Pelleted BAL cells were resus-
pended in 5 ml of sterile PBS and used for flow cytometry
(see below). Total cell counts were determined using a
haemocytometer and presented as cells/ml BAL fluid.
Differential cell counts (total of 200 cells) were performed
on cytospot preparations stained with Kwik DiffTM solu-
tion (Thermo Fisher Scientific, MA, USA) to enumerate
proportions of macrophages, lymphocytes, eosinophils
and neutrophils.
Cytokine detection in BAL samples
Protein levels of IL-4, IL-6, IL-10, IL-13 and TNF-α in
BAL samples were determined using ovine-specific ELI-
SAs. Antibodies and standards used are detailed in Table 1,
with IL-4, IL-6, IL-10 and TNF-α ELISA protocols as pre-
viously reported [29–31], and the IL-13 ELISA protocol
developed and optimized in-house.
BAL cell characterization by flow cytometry
For intracellular cytokine staining, BAL cells were resus-
pended in cell culture medium (DMEM containing 10 %
Table 1 Details of reagents used in ovine-specific cytokine ELISAs
ELISA Antibody (Ab)/cytokine details Clone/type Dilution Source
IL-4 rov IL-4 (cytokine standard) - - Moreduna
Anti-bovine IL-4 mAb (coating) CC313 1:400 AbD Serotecb
Anti-bovine IL-4/biotinylated mAb (detecting) CC314 1:1600 AbD Serotec
Streptavidin/HRP - 1:1000 Dakoc
IL-6 rov IL-6 (cytokine standard) - - CABd
Anti-ovine IL-6 mAb (coating) 4B6 1:400 Epitopee
Anti-ovine IL-6, pAb (detecting) rabbit pAb 1:5000 CAB
Anti-rabbit Ig/HRP - 1:1000 Dako
IL-10 rbov IL-10 (cytokine standard) - - Moredun
Anti-bovine IL-10 mAb (coating) CC318 1:200 AbD Serotec
Anti-bovine IL-10/biotinylated mAb (detecting) CC320 1:1000 AbD Serotec
Streptavidin-HRP - 1:1000 Dako
IL-13 rbov IL-13 (cytokine standard) - - Kingfisherf
Anti-bovine IL-13, pAb (coating) rabbit pAb 1:800 Kingfisher
Anti-bovine IL-13/biotinylated pAb (detecting) rabbit pAb 1:2000 Kingfisher
Streptavidin/HRP - 1:1000 Dako
TNFα rov TNFα (cytokine standard) - - CAB
Anti-ovine TNFα mAb ascites (coating) 6.09 1:200 CAB
Anti-ovine TNFα pAb (detecting) rabbit pAb 1:500 CAB
Anti-rabbit Ig/HRP - 1:1000 Dako
rov Recombinant ovine, rbov Recombinant bovine, mAb Monoclonal antibody, pAb polyclonal antibody
aMoredun: Dr Gary Entrican, Moredun Research Institute, Edinburgh, Scotland
bAbD Serotec: AbD Serotec, UK
cDako: Agilent Technologies Inc., CA, USA
dCAB: Centre for Animal Biotechnology, School of Veterinary Science, Melbourne, Australia
eEpitope: Epitope Technologies Pty Ltd, VIC, Australia
fKingfisher: Kingfisher Biotech, Inc, MN, USA
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fetal bovine serum (FBS) and 0.1 % gentamycin; Life Tech-
nologies, CA, USA) at 106 cells/ml and incubated in the
presence of Brefeldin A (20 μg/ml; Cell Signaling Technol-
ogy, MA, USA) for 2 h, then washed and resuspended in
intracellular blocking buffer (PBS, 0.1 % saponin, 5 % nor-
mal horse serum, 5 % normal sheep serum (NSS), 5 %
FBS, 0.01 % sodium azide) to reduce non-specific binding.
Cells were then incubated for 30 min at 4 °C with anti-
bodies (Abs) to IL-4 (FITC-conjugated anti-bovine IL-4
mAb, 1:100; AbD Serotec, UK), or IL-13 (rabbit anti-
bovine IL-13 polyclonal antibody (pAb), 1:100; King-
fisher Biotech Inc., MN, USA) with matching secondary
Ab (Alexa FluorTM 488 goat anti-rabbit IgG, 1:200;
Jackson ImmunoResearch Laboratories Inc., PA, USA).
Cells were washed and fixed in 2 % paraformaldehyde
(PFA; Fluka, St. Gallen, Switzerland) in PBS and stored
at 4 °C prior to analysis by flow cytometry. Leukocyte
cell populations were gated on the basis of forward
scatter (FSC) and side scatter (SSC) characteristics [23]
and 10,000 events were acquired using a BD LSR II
flow cytometer (Becton Dickinson Biosciences, CA,
USA), with data analyzed using FlowJoTM software
(TreeStar Inc, OR, USA).
Immunostaining of lung tissue
Lung tissues were collected at post-mortem, 48 h post-
allergen challenge, and embedded in Optimal Cutting
Temperature (OCT) medium (Tissue Tek, Miles Inc.,
PA, USA) and stored at −80 °C prior to immunostain-
ing. Frozen tissue sections (5 μM) were cut onto glass
microscope slides, then air-dried and fixed in 2 % PFA.
Slides were washed in PBS/ 0.1 % Tween 20 and incu-
bated with anti- IL-4 (anti-bovine IL-4 mAb, 1:100,
clone CC313; AbD Serotec) or a combination of anti-
IL-13 (as detailed above) and anti-CD45 (common
leukocyte marker; [32]) antibodies. Secondary Abs
included Alexa FluorTM 594 anti-mouse Ig (1:1000; Life
Technologies) for IL-4 and CD45, and Alexa FluorTM
488 anti-rabbit IgG (1:200; Jackson ImmunoResearch)
for IL-13 detection. Slides were then washed and
mounted with Mowiol mounting medium (Calbiochem,
CA, USA) containing 4′, 6-diamidino-2-phenylindole,
dihydrochloride (DAPI, 1:5000; Life Technologies).
Statistical analysis
To assess the effect of saline or HDM challenge as well
as time following challenge on BAL cell numbers, cell
percentages, cytokine levels and cytokine expressing
cells, a two-way ANOVA test was performed followed
by a Holm-Sidak test to correct for multiple compari-
sons. Differences were considered significant for p <
0.05. All data are reported as the mean ± standard devi-
ation (SD).
Results
Analysis of BAL cells following airway allergen challenge
BAL leukocyte numbers from HDM- and saline- chal-
lenged lungs before and at 4, 24 and 48 h post-challenge
are shown in Fig. 2. In saline-challenged lobes there was
little change in leukocyte numbers across the different
time points. Conversely, in HDM-challenged lung lobes
there was initially a decline in total BAL leukocyte
number at 4 h, followed by a significant increase by 24 h
post-challenge (Fig. 2).
While macrophages were the major cell component in
BAL, there was an initial decline in numbers at 4 h after
saline or HDM challenge, followed by a return to similar
baseline levels within 48 h post-challenge (Fig. 3a). Mac-
rophages represented ~90 % of BAL at baseline but this
was reduced at all time points post-challenge (Fig. 3e).
Lymphocyte numbers showed little change over time
(Fig. 3b), although the percentage of lymphocytes in
BAL increased at 4 h in saline- and HDM- challenged
lobes compared to pre-challenge (Fig. 3f ). There was a
significant increase in neutrophils in BAL over the first
4–24 h after saline or HDM challenge (Fig. 3c, g). In
contrast, eosinophils that were absent in BAL prior to
airway challenge were recruited into BAL following
HDM challenge, reaching their maximum at 24–48 h
(Fig. 3d, h).
BAL cytokine profiles
IL-4, IL-13, IL-6, IL-10 and TNF-α levels were assessed
in BAL samples collected after saline or HDM challenge
(Fig. 4). BAL IL-4 levels were greater in HDM-
challenged lobes compared to saline at 4 h but decreased
between 4 and 48 h after HDM challenge (Fig. 4a). IL-13
levels in HDM-challenged lobes were significantly higher
than saline-challenged lobes at each of the time points
examined (Fig. 4b). IL-6 levels at 4 h post-challenge
showed no significant difference between HDM and
saline treated lobes, while greater levels of IL-6 were
detected in HDM-challenged lobes compared to saline
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Fig. 2 Kinetics of leukocyte traffic into BAL fluid over time following
saline and HDM bronchial challenges. Data presented as mean
counts (cells/ml BAL) ± SD for n = 6 sheep (#denotes significant
difference; #p < 0.05)
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Fig. 3 Kinetics of leukocyte sub-population traffic into BAL fluid over time following saline and HDM bronchial challenges, showing changes in
(a–d) cell number and (e–h) cell percentage over time. Data presented as mean counts ± SD for n = 6 sheep (*denotes significant difference
between HDM and saline-challenged lobes at the corresponding time point: *p < 0.05, **p < 0.01; #denotes significant difference between time
points: #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001)
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Fig. 4 Cytokine protein levels over time (0–48 h) showing (a) IL-4, (b) IL-13, (c) IL-6, (d) IL-10 and (E) TNF-α in BAL fluid following saline and HDM
bronchial challenges. Data presented as means ± SD for n = 10 sheep (*denotes significant difference between HDM and saline-challenged lobes
at the corresponding time point: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; #denotes significant difference between time points: #p < 0.05,
##p < 0.01, ###p < 0.001, ####p < 0.0001)
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at 24 and 48 h (Fig. 4c). Further, there was a significant
decline in BAL IL-6 levels from the 0 h/4 h time-point
to 24 and 48 h after saline challenge. IL-10 levels were
increased at 4 h and decreased at 48 h in HDM-
compared to saline-challenged lobes (Fig. 4d). TNF-α
levels in HDM-challenged lobes were similar to saline-
challenged lobes at the examined time points and there
was no change in BAL over time (Fig. 4e).
Intracellular expression of IL-4 and IL-13 in BAL cells
BAL cell subpopulations were identified in the pre- (0 h)
and post-challenge (4 h, 24 h, 48 h) BAL samples, with
gating based on forward- and side- light scatter (FSC,
SSC) properties as reported elsewhere [23]. BAL cell
subpopulations were then examined for intracellular IL-4
and IL-13 expression and analyzed by flow cytometry.
There was a marked but transient increase in the pro-
portion and total number of IL-4+ lymphocytes from 0
to 4 h in HDM-challenged lungs, followed by a return to
baseline levels from 24 h post-challenge; the increase in
IL-4 expression at 4 h was significant compared to
saline-challenged lobes at that time-point (Fig. 5a & d).
There was a significant increase in the percentage and
total number of IL-4+ macrophages at 24 h post-HDM
challenge compared to earlier time-points and saline
challenge (at 24 h), with a subsequent decline to baseline
levels at 48 h post-challenge (Fig. 5b & e). Of the granu-
locytes recruited into the lungs at 24 h post-HDM chal-
lenge, the proportion and the total number of these cells
expressing IL-4 was greater in HDM- compared to
saline-challenged lobes, although no difference was ob-
served at 48 h (Fig. 5c & f).
A significant decline in the proportion of lymphocytes
expressing IL-13 was seen in both saline- and HDM-
challenged lobes from 4 to 24 h post challenge followed
by an increase in saline-challenged lungs at 48 h (Fig. 6a);
a similar pattern of change in cell number was seen fol-
lowing saline challenge (Fig. 6d). The percentage of IL-
13+ macrophages in HDM-challenged lobes was higher
than in saline-challenged lobes at 4 and 24 h post-
challenge (Fig. 6b). In HDM-challenged lungs, there was
a decrease in the proportion of macrophages positive for
IL-13 from 4 to 24 h, followed by an increase in the pro-
portion (but not total cell number) of both macrophages
and granulocytes at 48 h (Fig. 6b, c, e & f). The total
number of IL-13 expressing macrophages was not
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Fig. 5 IL-4 detection in BAL cells following saline and HDM bronchial challenges. a–c percentage and (d–f) total numbers (cells/ml BAL) of IL-4
expressing lymphocytes, macrophages and granulocytes collected at 0 h (baseline), and at 4, 24 and 48 h post-segmental airway challenge. Data
presented as mean positive cells (within subpopulation) ± SD for n = 6 sheep (*denotes significant differences; *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001; #denotes significant difference between time points: ##p < 0.01, ###p < 0.001, ####p < 0.0001)
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significantly altered in HDM-challenged lobes but the
number of these cells in saline-challenged lobes in-
creased at 48 h compared to 4 and 24 h (Fig. 6e).
IL-4 and IL-13 expression in lung tissue
Post-mortem lung tissues were collected 48 h after a
HDM allergen challenge and frozen tissue sections cut
for immunostaining to examine IL-4 and IL-13 expres-
sion (Fig. 7). Intracellular expression of IL-4 and IL-13
was observed in cells within the lung tissues, and this
was localized particularly within and below the epithelial
layer (Fig. 7b and d). Dual staining of the lung tissue sec-
tions for IL-13 and CD45 (leukocyte common antigen)
clearly showed that IL-13 was expressed in both immune
(IL-13+CD45+) and non-immune (IL-13+CD45−) cells
within the HDM-challenged airway tissues (Fig. 7d).
Discussion
The pathophysiological features of allergic asthma are
characterized by airway inflammation and structural and
functional changes in the lung. These responses are di-
rected by the actions of a number of key cytokines. IL-4
and IL-13 are two such cytokines that have been shown
to play a central role in directing the pathophysiological
changes in allergic asthma [3]. The role of Th2 cytokines
has been extensively studied in small animal models of
asthmatic disease and much of our current understand-
ing arises from basic mechanistic, knockout and trans-
genic studies, and therapeutic interventions [26]. There
is clear potential and much interest in the development
of targeted anti-Th2 cytokine therapies for asthma [33].
However, mixed success with regard to anti-IL-4 and
anti-IL-13 interventions in clinical trials to date [19, 20]
confirms the need for a better understanding of the
mechanisms of pathogenesis underlying the different
Th2 ‘endotypes’ seen in asthma [34–37]. The ability to
perform detailed kinetic studies and real-time measure-
ments as well as dose—response efficacy studies and
therapeutic interventions, requires the development and
validation of large animal models that provide clarity of
disease onset and progression. Such investigations will
help to improve our understanding of the role for IL-4
and IL-13 in human asthmatic disease and identify
effective, targeted therapeutic strategies [22].
There is comparatively little known about the role for
Th2 cytokines in allergic airways disease in larger animal
IL-13+lymphocytes IL-13+macrophages IL-13+granulocytes
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Fig. 6 IL-13 detection in BAL cells following saline and HDM bronchial challenges. a–c percentage and (d–f) total numbers (cells/ml BAL) of IL-13
expressing lymphocytes, macrophages and granulocytes collected at 0 h (baseline), and at 4, 24 and 48 h post- segmental airway challenge. Data
presented as mean positive cells (within subpopulation) ± SD for n = 6 sheep (*denotes significant differences; **p < 0.01, ***p < 0.001; #denotes
significant difference between time points: #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001)
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models such as dog, sheep, horse and non-human pri-
mates, although it appears Type 2 or Th2 immune path-
ways are involved, establishing some parallels between
these larger animal models and human allergic asthma
[26, 38–40]. In the present study we used a sheep model
of allergic asthma to investigate the kinetics of expres-
sion of IL-4 and IL-13 in allergen-challenged airways,
with the goal to extend our understanding of Th2-driven
mechanisms in this large animal model system.
IL-4 and IL-13 are required for the IgE class switching
in B lymphocytes [41], and increased BAL levels of IL-4
and IL-13 are consistent with elevated allergen-specific
IgE in serum [23, 28] and BAL fluid [28] in the sheep
asthma model. The early elevation of these Th2 cytokines
followed by the recruitment of neutrophils, lymphocytes
and macrophages in this model, precedes the late phase
allergic response associated with the appearance of eosin-
ophils from 24 to 48 h after allergen exposure. The fact
that eosinophils were detected in saline-treated control
lung lobes might suggest some degree of a systemic (ie
lung-wide) response to segmental lung allergen exposure
in this model. Indeed, altered BAL cellularity in control
lobes has also been observed by others that have used re-
peated segmental airway challenge to study inflammation/
infection in sheep [42]. In our own experience and that of
others [43], it has been shown in sheep that repeated BAL
sampling has no effect itself on BAL cellularity over time,
and sampling from different lung lobes is comparable.
We found elevated IL-4 levels in BAL across all time-
points examined following allergen challenge. Lympho-
cytes, most likely CD4+ T cells [23], were a major source
of IL-4 in the immediate hours (4 h) after allergen chal-
lenge, while IL-4 expressing alveolar macrophages (AMs)
were predominant in BAL at the later (24 and 48 h) time-
points. IL-13 was elevated in BAL at 4 h post challenge,
with lymphocytes (4 h) and AMs (4–48 h) found to be the
major sources of IL-13 post allergen challenge. The
immunostaining of airway tissue showed that the bron-
chial epithelium also serves as a cellular source for IL-13
in sheep airway tissues following allergen challenge, simi-
lar to that reported elsewhere [44]. Eosinophils and mast
cells may also be a source of IL-4 and IL-13 [3, 4], and
in this study and earlier investigations these cells have
been shown to be a key feature of the inflammation
seen in the sheep model of allergic asthma [22]. Indeed,
the greater levels of intracellular IL-13 expression in BAL
granulocytes from 24 to 48 h post-allergen challenge is
associated with an increased eosinophil recruitment into
a b
c d
Fig. 7 Immunostaining of IL-4 and IL-13 in lung tissues following allergen challenge, showing (a) negative staining (isotype-matched control Ab),
(b) IL-4+ cells (red, arrows), (c) CD45+ leukocyte (red) staining, and (d) CD45+ (red) and IL-13+ (green, arrows) staining; the arrow shows an IL-13
expressing leukocyte (IL-13+CD45+) and the arrow head shows an IL-13 expressing non-leukocyte (IL-13+CD45−). Representative sections were
taken from the same lung lobe of a sheep, collected post-mortem at 48 h post-HDM challenge. All slides were counterstained with DAPI (blue)
when mounted in Mowiol (Original magnification × 400)
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BAL at this time. While not shown in the present study, a
significant correlation between IL-13 expression and
eosinophils in BAL has been reported elsewhere [14, 15].
The elevated IL-4 and IL-13 levels seen in the present
study reinforces the idea that Th2 lymphocytes are key
cellular players in directing the early immune response
to allergen re-exposure in the sheep asthma model.
Moreover, our observations with respect to the cellular
source of these cytokines also implicate significant
changes in the airway macrophage population and their
involvement in the pathophysiology of allergic airway
responses in sheep.
AMs are the principal cellular sentinels of the respira-
tory tract that are continually exposed to potentially in-
flammatory stimuli, and there is good evidence to suggest
they become differentially activated during asthma re-
sponses [45]. Both IL-4 and IL-13 are involved in the
alternative activation, or differentiation of the ‘M2 class’, of
macrophages [46, 47] and recent studies have identified
important roles for airway macrophages in allergic inflam-
mation, including promotion of Th2 reactivity and airway
tissue remodelling [48, 49]. M2 macrophages have been
shown to be more abundant in the BAL and airway tissues
of asthmatics compared with healthy subjects [50]. Fur-
ther, enhanced levels of IL-13 producing macrophages
have been found in the BAL from subjects with severe
asthma, suggesting that M2 macrophages may contribute
to reduced lung function in asthma patients [51].
In the present study, there was an initial decline ob-
served in AM numbers following allergen challenge but
also a clear shift in their functional phenotype, with an
increase in the proportion of IL-4 (24 h) and IL-13 (4
and 24 h) producing AMs, suggesting the emergence of
alternatively activated macrophages [52, 53] and a likely
contribution to the key pathophysiological features of
the sheep allergic asthma model. We have also found in
preliminary studies that AMs collected from sheep asth-
matic airways are altered in their ability to release cyto-
kines in response to various stimuli, and display a
diminished capacity for phagocytosis ex vivo (Liravi et
al., unpublished data), typical of the changes seen in al-
veolar macrophages in asthma [54]. While it was shown
that IL-13 expression in AMs was elevated at 4 and 24 h
in allergen challenged airways, we found a similar pro-
portion of IL-13 expressing AMs in saline and allergen-
challenged airways at 48 h. Constitutive expression of
IL-13 by AMs in normal subjects and elevated expres-
sion in subjects with airway disease may reflect the
broad role for IL-13 in homeostasis and disease [49, 55].
IL-4 is known to direct the differentiation of AMs and
their release of pro-inflammatory cytokines such as IL-6
and TNFα [56]. In the present study TNFα levels in BAL
showed minimal change following allergen or saline ex-
posure, however BAL IL-6 levels were elevated at all time-
points in response to allergen, with Th2 lymphocytes,
AMs and/or airway epithelial cells [31] the most likely
source. Indeed, the inflammatory pathways underlying
mucus hyperplasia and AHR seen in the sheep asthma
model may be partly dependent on IL-6 signalling, al-
though the contribution of classical or IL-6 trans-
signalling, as recently investigated in mice and human
subjects [57], is yet to be elucidated in the sheep model.
IL-10 levels in BAL were highest at 4 h but lower at 48 h
following allergen challenge compared to saline challenge.
In the present study we did not investigate the cellular
source of IL-10. However, sheep AMs are able to produce
IL-10 in response to IL-13 ex vivo (Liravi et al., unpub-
lished data) and macrophages from asthmatics are known
to secrete elevated IL-10 levels [58]. On the other hand,
Tregs (regulatory T lymphocytes) could also be a source
of IL-10, although these cells are less functional and their
numbers are reduced in asthma [59].
IL-4 and IL-13 overwhelmingly have an impact on air-
way inflammation, directing the recruitment and activa-
tion of immune cells including airway dendritic cells,
alveolar macrophages, eosinophils, mast cells and neutro-
phils, mucin production by airway epithelial cells and
airway wall remodelling in response to allergen exposure
[4, 12]. These features have all previously been reported in
the sheep asthma model [24, 28], and together with find-
ings from our present study on cytokine data not previ-
ously documented for any other large animal model of
asthma, strongly implicates a role for Th2 cytokines in the
inflammatory and disease processes in this model system.
Future studies in the sheep asthma model may investi-
gate the changes in expression and subsequent therapeutic
targeting of other Th2-associated mediators such as IL-17,
IL-22, IL-25 and IL-33 [60–63], or miRNAs thought to
play a role in directing the pathways of IL-4 and/or IL-13
production in allergic airways, including miR-21, miR-145
and miR-155 [64–67].
Conclusion
The results of this study provide further insight into the
kinetics of cytokine expression in allergen-challenged
airways, and for the first time in a large animal model
demonstrate a Th2 polarized cytokine profile featuring
IL-4 and IL-13 associated with allergen-induced airway
inflammation.
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